research team 2 (IMAGE)
Caption
Following the significant effects of the ‘dual immunotherapy’, the new combination treatment has been approved from the FDA, EMA and NMPA for previously untreated advanced HCC patients. The research team includes (from left) Professor Cheung Tan-to, Dr Thomas Yau Chung-cheung and Dr Ronald Leung Ching-yu.
Credit
The University of Hong Kong
Usage Restrictions
N/A
License
Original content